Juva Life Initiates Clinical Registry as First Step in Building Evidence-Based Cannabis Technology Platform

Juva Life Initiates Clinical Registry as First Step in Building Evidence-Based Cannabis Technology Platform

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 21, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,“Juva” or the “Company”), a California-based life science company today announces the launch of a clinical registry to evaluate rationally designed cannabis formulations for clinical effect and mode of action. This is the first step towards building an integrated technology platform addressing serious and unmet medical needs.

There is a substantial body of pre-clinical, clinical, and anecdotal data consistent with a cannabis effect, but despite significant investment and opportunity, there is an absence of understanding of “how cannabis works” to pair the right formulation with the right indication. Juva has designed a novel technology platform spanning natural products pharmacology, clinical science, and digital learning. As part of this effort, Juva will employ FDA-approved metrics and best practices to validate the clinical safety and efficacy of formulations derived from our platform.

On August 25, 2020, the Juva Life-sponsored Informed Patient Cannabis Therapy Registry (The IMPACT Registry) was approved by the WCG IRB. Recognized as the gold standard of human research protection, the WCG Institutional Review Board is a trusted partner to more than 3,100 research institutions in the USA. The IRB has approved two locations to be used in the research and Juva’s team is working with the research facilities regarding protocols, methodologies, and recruitment of a cohort of up to 2,000 volunteer patients.

Juva Life is addressing the unmet need for small molecule anti-inflammatory consumer and pharmaceutical products initially targeting pain. A significant percentage of patients who are using cannabis are self-medicating for untreated/incompletely treated pain. This presents a substantial problem for physicians and ultimately regulatory agencies. Frequently patients resort to cannabis products when conventional drugs fail, and they exclude healthcare providers from these decisions. They correctly perceive either a lack of knowledge or belief of a cannabis effect on the part of their physicians and care providers. Juva Life is addressing this knowledge gap by developing evidence-based products that meet the needs of physicians and patients.

The current approach to cannabis research and development is largely empirical. Absent is a (new) way to quantify the clinical effect and mode of action of compounds contained within cannabis. Juva Life has developed a way to decipher and systematically evaluate the chemistry of cannabis more efficiently with less cost and reduced timelines than current practices. The Juva platform aims to develop an efficient way to standardize the development and testing of complex natural product mixtures. Central to this is a clinical registry patterned after pharmaceutical drug development best practices. By combining know how concerning mode of action, with FDA approved clinical endpoints, Juva will speed the collection of valuable evidence-based data sets to evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships, target engagement and clinical efficacy.

Juva is one of the very first companies to develop a cannabis platform to decipher the putative clinical effects of cannabis. We intend to be a world leader at the pharmacology of complex cannabis mixtures, and the development and commercialization of standardized products that meet pharmaceutical evidentiary standards. The pillars of our platform center on identification of compounds that alone or in tandem exhibit reproducible pre-clinical effects; validation in human subjects employing standard disease metrics; development of consumer and pharmaceutical products that meet the highest safety and efficacy standards; and the commercialization alone and through partnerships of products derived from our pipeline.

Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, “Our mission is to use state of the art life science and data technologies to understand how cannabis works. There is a significant need for new solutions to serious diseases where cannabis may play a role. Our goal is to address these unmet medical needs and when coupled with our novel learning and revenue model, build a durable, important, and valuable company. The months and years ahead represent an extraordinary opportunity as we unlock that enormous potential of cannabis.”

In related news, the Company advises it has engaged the services of Creative Direct Marketing Group Inc. (CDMG) a full-service direct response advertising and digital marketing agency to increase public and investor awareness for a period of six months, for the agency fee of $2.107 million.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
inquiries@juvalife.com

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

 


 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Receives California Cultivation License for Stockton Facility

Juva Life Receives California Cultivation License for Stockton Facility

— Milestone Event to Spur Revenues and Product Development Pathway for Unmet Medical Needs

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 19, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is extremely pleased to announce receipt of a state approved cannabis cultivation license for its almost 30,000 sq. ft.  facility located in Stockton, California.

After approximately 30 months of dedicated effort encompassing a comprehensive regional and municipal permitting process, extensive physical upgrades, and state of the art equipment installations, Juva has received a greenlight from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture (CDFA). The agency ensures public safety and environmental protection by licensing and regulating commercial cannabis cultivators statewide. CalCannabis also manages the state’s track-and-trace system, which tracks all commercial cannabis and cannabis products—from cultivation to sale.

With licensing approval, Juva is now moving swiftly to fully activate its newly upgraded facility by planting approximately 8,000 sq. ft. of flowering canopy and 5,000 sq. ft. of non-flowering canopy. An additional 4,500 sq. ft. of space has been subdivided into trim, dry storage, breeding, pre-roll, packaging, and environmental system rooms (including automated controls, water reserves, fertilization, and irrigation, etc.). Three of the five growing spaces are ready for immediate planting with another two expected to be completed by Q2, 2021. Once all five rooms are fully operational, the facility is expected to have the annual capability to produce approximately 6,000-pounds of high-quality cannabis flower. Cultivated flower production is slated for use in Juva branded products, contract production services, and clinical research targeting novel product formulations.

In addition, the facility includes almost 3,000 square feet of space for use as a delivery, packaging and distribution center. As of October 2020, Juva has operated a growing cannabis delivery fleet from this location, offering nearly 400 product SKU’s to the approximately 750,000 residents of San Joaquin County.  Plans for 2021 include expanded delivery services to the municipalities of Tracy (to the west), Modesto, (to the south) and Elk Grove (to the north).

The facility provides the residential delivery service separately from the distribution center which is designed to service B2B shipping of bulk cannabis to other licensed cannabis businesses (including related Juva facilities) as well as planned distribution of Juva branded products. The entire facility has been outfitted to be completely powered by low emission onsite natural gas generators so that electrical grid power serves as a system backup in order to reduce electrical operating costs by as much as 50%.

Company Founder and CEO, Doug Chloupek states, “This is a milestone event for Juva. Now that we can commence cultivation, we are firmly in charge of our destiny. We can control product quality and output in order to service our growing enterprise, as well as generate quantifiable returns. Our strategy integrates a path to sustainability and an ability to advance the development of novel formulations to address a myriad of unmet medical needs around the world. Todays announcement is a huge step forward and validation of our business plan to build value at every step of the process.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 


About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com


Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Unifies and Accelerates Brand Marketing Plans

Juva Life Unifies and Accelerates Brand Marketing Plans

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 14, 2021) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,“Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations, is pleased to announce an upcoming strategic brand identity campaign designed to unify its messaging amongst its various products and divisions. 

Juva Life is working to unify its communication strategy and advance its brand positioning in order to more consistently represent its core mission across multiple platforms and media. The Company is embarking on an accelerated plan for growth, and as such, the need for responsible broad public awareness is increasingly paramount for the long-term success of the Company.

Company Founder and CEO, Doug Chloupek states, “Our Life Sciences efforts are instrumental for the strategic success of Juva. While our efforts to-date have laid the foundation for a solid regional cannabis enterprise, we are actively pursuing opportunities aimed at delivering a platform of products that address significant unmet medical needs. The marketing efforts required to drive awareness of our activities includes considerable forethought and planning to ensure consistent messaging to appropriately communicate the various aspects of our product development strategy. We are dedicated to laying a solid foundation for commercial success by executing a comprehensive strategic marketing plan.”

The Company has implemented a scalable approach to marketing by engaging contract vendors who meet the requisite needs for creative expertise, cost-effective methodologies, and the ability to provide a long-term perspective in a fast-paced, evolutionary environment.

As a result, Juva is incredibly pleased to be working with a growing team that includes The Idea Cooperative, a dedicated full-service creative agency of Sonoma County, California who have taken the lead role in consumer-facing brand positioning and product design. Their talents are focused on website, social media, newsletters, and other related commercial communications strategies. In addition, Juva has engaged the highly experienced, full-service design team at August Studio of Oakland, California to integrate a consistently branded look and feel throughout its brick-and-mortar facilities.

In related news, the Company has engaged investment communications, financial research, and integrated digital marketing service providers to increase public awareness regarding Juva’s activities, strategic plans, and investment opportunity. As part of Juva’s disclosure obligations as a public issuer, the terms and fees for investor relations service providers are six (6) month engagements and include Advanced Media Solutions Ltd. at $450k, Promethean Marketing Inc. at $350k, and Digitonic at $150k.

Together, these creative, communications and marketing agencies are shaping the future brand identity and public awareness of Juva Life.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 


About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com


Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Brings Bold Outlook for the New Year

Juva Life Brings Bold Outlook for the New Year

— Science, medicine, and business expertise to create evidence-based cannabis opportunity

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 4, 2021) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to offer insights into activities and strategic actions for the coming year.

Company Founder and CEO, Doug Chloupek states, “As previously announced, our activities in the San Francisco Bay Area and the Central Valley are well underway with our delivery services generating growing revenues from our Redwood City and Stockton operations, and our plans are moving ahead with permitting, licensing and construction activities at our Hayward and Stockton facilities. We are just months away from increasing our revenue capability as our new facilities scale up and go online. Combined with the introduction of our advisory team in early December, we are now able to activate our proposed Life Sciences strategy for the new year.”

Juva is addressing the absence of reliable and reproducible evidence-based cannabis products that individuals can rely upon for their health needs. With the development of a proprietary technology platform to standardize and clinically validate cannabis-based products, Juva will address the need for safe evidence-based cannabis products aimed at targeting serious medical illness. In doing so, Juva will address the needs of patients/consumers, regulators, healthcare providers and commercial partners.

Juva Life’s strategy mirrors the best practices of the ethical pharmaceutical industry coupled with a modern learning strategy to develop evidence-based products faster and at a lower cost basis. This provides dual benefits to patients who desire new products to treat their needs as well as to investors who have the potential to see accelerated value creation. The cornerstone of our platform is the standardization and clinical validation of complex natural products such as cannabis.

Juva’s platform consists of the following core elements:

• IDENTIFICATION: Novel chemistry platform identifies combinations of bioactives that work together across multiple modes of action.

• VALIDATION: Evidence-based clinical development platform coupled to advanced data science tools.

• PRODUCTIZATION: Address unmet medical need spanning consumer and pharmaceutical categories.

• COMMERCIALIZATION: Vertically integrated to enable efficient unlocking of value.

“We envision a new type of cannabis company” said Chloupek. “By introducing expertise in the science of cannabis we reduce development and discovery risk, and by employing expertise in the business of cannabis we can reduce commercial risk. Through this framework we have a solid strategy to leverage our regional revenue generation through investment in peer evaluated, scientifically developed formulations that aim to offer value-multiplied licensing opportunities to a potentially global audience. If we can prove efficacy and safety with products that consumers desire, then there is a quantifiably great opportunity ahead. That’s how we aim to build a sustainable business model and grow shareholder value.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com


Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Transforming Ex-Cancer Research Facility into Flagship Operation

Juva Life Transforming Ex-Cancer Research Facility into Flagship Operation

– Hayward Research Laboratory Positioned to Drive ‘Science of Cannabis’ Efforts

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 22, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,“Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to provide an update regarding activities at its Hayward, California facility build-out.

Originally constructed and partially funded by federal research grants, Juva Life’s Hayward project started life as biotechnology cancer research facility focused on the development of plant-based antibodies and the study of protein expression in tobacco plants. As such, the structures on the property includes 18,000 sq. ft. of preexisting purpose-built concrete structures adjoining 11,000 sq. ft. of dedicated greenhouse canopy.

As part of the legacy infrastructure and a key feature in Juva’s future ambitions, the main building includes an ISO Class 5 cleanroom ideally suited to propel Juva’s science of cannabis strategy towards the development of advanced formulations and products. The cleanroom and adjoining laboratory spaces include plans for the installation of liquid and gas chromatography plus mass spectrometry equipment. Class 5 is considered at the more critical end of the class spectrum, requiring a greater level of filtration to achieve a level of cleanliness by typically employing Ultra Low Penetration Air (ULPA) Filtration targeting 99.9995% efficiency at 0.12 micron. This research facility is scheduled to be one of the first operational elements of the Hayward campus.

A Conditional Use Permit (CUP) was approved on October 22nd upon completion of an extremely rigorous and thorough application process. The application included many details typically included in building permit applications and, as such, it is believed may expedite additional permitting. Upon approval, immediate actions require the installation of physical perimeter security and modernized fire suppression systems. Upon installation, the Company will apply for partial occupancy to enable the outfitting of the laboratory and related processing areas in order to initiate extraction and formulation operations which are anticipated to scale to full production by mid-2021.

Upon completion of the proposed renovations, greenhouse cultivation is conditionally approved for 13,453 sq. ft. within a fully modernized facility. An internal assessment suggests that material yields of up to 4,600 pounds of total biomass inclusive of 3,600 pounds of flower could be harvested in the first full year of activity. Advanced agronomic practices within the controlled environment are anticipated to produce quantifiably premium quality and potency. The Hayward facility will ultimately total 38,000 sq. ft. in size with a manufacturing focus on advanced industrial scale extraction processes utilizing most of the internally harvested material for use in novel formulations, product development, and material supply for Juva’s related divisional activities.

Related activities planned for the Hayward campus include business to consumer (B2C) retail delivery operations offering Juva-produced and 3rd party products throughout the Eastern San Francisco Bay area. Acting as a distribution center, Juva would have the ability to ship bulk or processed product to other licensed cannabis businesses (including other current or future Juva facilities). In addition, the Company has been conditionally approved to develop a boutique flagship retail operation focused on Juva products in a designer-styled environment.  

Juva’s CEO and Founder, Doug Chloupek states, “We were extremely fortunate to discover the Hayward location early in our planning phase. The previous occupants’ operations provide us with a pre-built facility that closely matches our strategic aims and consequently expedites our ability to advance operations. I’m particularly excited that it appears our lab could be functional early to mid 2021, as the development of a broad spectrum of product formulations through applied science is a fundamental aspect of how we aim to build corporate and shareholder value.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 


About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com


Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 


Juva Life Features Redwood City Operational Update

Juva Life Features Redwood City Operational Update

— Cannabis delivery services position Juva for post pandemic brand loyalty and growth

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 15, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,“Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to follow up on its November 25th news release with a featured summary of activities to-date at its Redwood City operations.

In relation to the significantly larger footprint of the Hayward and Stockton facilities which are rapidly advancing through licensing and construction phases, the Redwood City operation was designed to initially target regional delivery services and rapid territorial expansion. With a growing staff of over 14 team members and an expanding vehicle fleet which currently includes 50% hybrid electric vehicles, the service has been operational since late January of 2020.

With a functional capability to easily service the San Francisco Peninsula through its central location halfway between San Francisco and San Jose, the location serves a generally younger demographic in the Silicon Valley region. Ongoing efforts are underway to extend the delivery area to encompass adjacent high density urban centres aimed at increasing the total accessible population to an estimated 1.67 million potential customers.

Through an evolving menu of almost 400 SKU’s to choose from, including numerous award-winning and top selling products, the Juva sales team is constantly improving conversion rates and building a loyal customer base. For more information on product services, visit: www.shopjuva.com/redwood-city/.

In related news, the Company has recently obtained the option to lease a high visibility retail location on a prime corner of downtown Redwood City in a concerted bid to receive one of up to six storefront retail licenses proposed to be granted via a merit-based process by the municipality of Redwood City. Working in conjunction with the existing delivery services operational center for inventory support, the addition of storefront retail could act as a regional brand multiplier and centralized focus for enhanced consumer awareness campaigns.

Juva’s CEO and Founder, Doug Chloupek notes, “COVID-19 created some surprising opportunities and interesting challenges that our team have been able to pivot to our advantage. As a brand-new delivery service offering an extensive menu of popular items, we really had to quickly build confidence based on quality, responsiveness, merit and trust. To-date, we have successfully proven to our growing list of customers that with Juva, they can easily order the products they want, when they want, and where they want them. As news regarding vaccine rollout build hope for future, we believe we are extraordinarily well positioned to leverage our commercial activities to quickly advance marketing momentum and increase our sector positioning as, and when restrictions begin to ease. We have worked hard to get the word out during these challenging times and our efforts will definitely act as a launch pad for continued growth and greatly assist in the creation of sustainable value for our entire enterprise.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

 


 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 


Juva Life Introduces Advisory Team in Preparation for Advancement Towards “Precision Cannabis”

Juva Life Introduces Advisory Team in Preparation for
Advancement Towards “Precision Cannabis”

— Medical and Science Team of Leading Experts Aim for Global Results

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 08, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations, is pleased to announce the launch of concerted efforts to develop “precision cannabis” products targeting the delivery of the “right formulation to the right individual at the right time.” Juva plans to develop intellectual property and secure patent protection on each of its custom formulations and will focus its research registries in areas of inflammation, oncology, neurology, pain management, sleep, menopausal symptoms, and opiate reduction.

 

Juva’s CEO and Founder, Doug Chloupek, has been the driving force in assembling a top team of leading professionals who come to Juva from major enterprises such as Bristol-Meyers Squibb, to prestigious high-profile organizations and academic institutions. These interdisciplinary experts are actively moving forward with research and data collection to support the creation of specialized formulations aimed at addressing a broad range of sometimes devastating disorders. As an outcome of the Company’s compelling vision and targeted recruitment efforts, the Company is pleased to introduce the following individuals and their respective roles as employees and advisors of the company. Together they bring an unparalleled level of experience from the medical and pharmaceutical industries to Juva.

 

Sanjeev Gangwar, Ph.D., VP of Chemistry

Previously served with Bristol-Meyers Squibb as Director of Oncology Discovery Chemistry where he successfully discovered and developed novel classes of cancer therapeutics during his tenure at this award-winning and globally recognized biopharma conglomerate. In his over 25-year career, Dr. Gangwar holds an impressive and extensive record of discovering and developing pharmaceutical drug candidates. Throughout his career he has focused on oncology and immuno-oncology research and held R&D leadership roles at several biopharmaceutical organizations. Dr. Gangwar is co-inventor of 45 patents, has co-authored over 40 peer-reviewed papers and has presented his work at numerous international conferences.

 

Guy Miller, MD, Ph.D., Chairman, Science Advisory Board

Dr. Miller is the Chair of Juva’s science advisory board. In this capacity, he is responsible for integrating our business and technical strategy into a unified Research & Development plan, and in steering our internal team and external experts towards key corporate objectives. Dr. Miller holds both a Ph.D. in chemistry and an MD, completing his training at the University of Chicago and Johns Hopkins School of Medicine. He is currently the founder and CEO of Wheel Biology, Inc., chairman of the board of directors, Pneumico, Inc. and an adjunct faculty member at Johns Hopkins School of Medicine, Department of Anesthesiology and Critical Care Medicine. He possesses broad expertise in natural products pharmacology, drug development, and innovation. 

 

Rakesh R. Patel, MD, Director and Chairman, Clinical Advisory Board

A renowned Oncologist and clinical researcher in the San Francisco Bay Area, with over 150 worldwide lectures and 100 publications to-date. In addition to precision oncology, Dr. Patel has a special interest in integrative medicine and has served on non-profit boards offering complementary therapies to cancer patients.  He is also a seasoned entrepreneur with multiple digital health healthcare start-ups. He is currently practicing in the Bay Area with Precision Cancer Specialists Medical Group. 

 

 

Peter Beitsch, MD, Science Advisor

Dr. Beitsch is an internationally recognized surgical oncologist and researcher. He holds several fellowships and is the former President of the American Society of Breast Surgeons.

 

Pat Whitworth, MD, Research Advisor

A leading researcher, educator and cancer surgeon, Dr. Whitworth completed his fellowship at the M.D. Anderson Cancer Center. He is a principal Investigator for numerous NCI and industry clinical trials.

 

Justin Lo, MD, Medical Advisor

Dr. Lo is a prominent specialist whose practice is respected and recognized for leading the way in effective pain management. Formerly, Dr. Lo was an Assistant Clinical Professor of Anesthesiology at the University of California, San Francisco. Currently he owns and manages comprehensive multidisciplinary pain management clinics throughout the Bay Area, specializing in non-opiate pain management.

 

To find out more about the Juva team visit:  https://juvalife.com/about/.

 

From Doug Chloupek, CEO: “Today, I am delighted to formally introduce our amazing medical and scientific leadership team. This gathering of innovative excellence is the true measure of where we are headed. Furthermore, we have assembled an outstanding executive team to advance our divisional cannabis operations in California to support our research and development efforts. Our mission lies in unlocking the medicinal benefits of Cannabis. The fields of inflammation, oncology and neurology are extensive and represent a potentially significant pathway to considerable value creation.”

 

In related news, Mr. Norton Singhavon has resigned effective immediately from the board to focus on his family and other full-time commitments. The Juva team thanks Mr. Singhavon for his dedication and commitment throughout the critical development stage of the Company and wishes him well in his future endeavours.

 

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

 

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

 

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

 

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

 

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 


Juva Life Begins Trading on Frankfurt Exchange with Ticker ‘4VV’

Juva Life Begins Trading on Frankfurt Exchange with Ticker ‘4VV’

Company provides summary of activities in California

VANCOUVER, BC, — (GLOBE NEWSWIRE – November 25, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,“Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and formulations, is pleased to announce the commencement of trading on the Börse Frankfurt exchange (FRA) under the ticker symbol “4VV.” Additionally, the international registry ISIN number is CA48222R1010 and the German WKN registry number is A2QHTZ. For those new to the Juva story a summary of past and future activities is outlined below and available on the Company website at www.juvalife.com.

Juva Life California Subsidiary

Juva Life Inc. USA, a California corporation and wholly owned subsidiary of Juva Life Inc. (as of May 30, 2019) was originally incorporated in 2018 and represents the culmination of decades of concentrated effort in the cannabis sector. Juva Stockton Inc. a wholly owned subsidiary of Juva Life Inc holds a Conditional Use Permit (“CUP”) from the city of Stockton, California which, subject to certain conditions, permits the Company to cultivate, manufacture, distribute and deliver cannabis for the medical and recreational markets within the State. Juva Stockton successfully launched its delivery service from this location in October 2020. Additionally, in October 2020, after a 2.5-year process, Precision Apothecary Inc, a wholly owned subsidiary of Juva Life Inc, now holds a CUP allowing for a Microbusiness operation in the City of Hayward, California. This permit will allow Juva to cultivate, manufacture, formulate, research, distribute and operate a retail cannabis storefront and delivery business in that municipality. Concurrently, the Company’s Redwood City delivery location has been fully operational since February 2020 and has experienced double-digit growth month over month since commencement of operations.

Capital Raise

On May 31, 2020, Juva Life closed a private placement financing with cumulative gross proceeds in excess of $18,000,000. As of June 30, 2020, the Company had working capital of $8,270,000 (excluding warrant liability). Use of funds to-date includes costs for facility construction and equipment, licensing and permitting, marketing, branding, staff recruitment and implementation of sales personnel, pipeline project acquisitions and general administration.

Corporate Divisions

The Company is made up of six divisions: Cultivation, Research, Manufacturing, Distribution, Retail and Delivery. Each division services specific vertical markets within a fully integrated framework under the guiding premise of commercially engaging the many ways cannabis can fundamentally improve individual quality of life.

Strategic Plan

Juva Life’s strategic plan is to be a fully autonomous, vertically-integrated cannabis business with two primary missions: (1) to achieve the lowest cost of production by owning licenses for retail sales, manufacturing, distribution and cultivation of cannabis and to employ each license to propel our supply chain with select brick and mortar storefronts and multiple delivery businesses throughout the State of California; and (2) to develop “precision cannabis” products that deliver the right formulation to the right individual at the right time. Juva plans to develop intellectual property and secure patent protection on each of its custom medical formulations and will focus its research registries in areas of inflammation, oncology, neurology, pain management and opiate reduction.

Management & Advisors

Led by Founder & CEO Doug Chloupek, the Juva Life team brings over 20 years management experience in the cannabis sector. Their knowledge and experience provide operational oversight in navigating the regulatory framework of the California cannabis market. Additionally, the Company has attracted an advisory board of highly respected and influential doctors, clinicians, and researchers from fields of medicine that range from pain management to oncology. Find out more about our team at https://juvalife.com/about/.

Production, Operations and Management Facilities

Juva Life currently has five leased properties and one option to lease space in the cities of Stockton, Hayward and Redwood City, California, and is in the process of building out its facilities and obtaining the necessary State and local authorizations to undertake its current and proposed operations.

Stockton, California

San Juan and Navy Drive Facilities

Currently developing two locally permitted cannabis production facilities totaling approximately 41,448 square feet, including: (1) an approximate 30,000 square foot production facility located on San Juan Drive in Stockton, California; and (2) an approximate 11,448 square foot facility located on Navy Drive in Stockton, California. These facilities will support cultivation, manufacturing, retail sales (non-storefront delivery only) and wholesale distribution supporting direct-to-consumer delivery operations in the north San Joaquin Valley as well as operate as the Corporation’s Central Valley distribution hub.

The San Juan facility is fully licensed by the city and state for delivery services and began Non-storefront retail (delivery) in October 2020.  The facility is licensed by the city for cultivation, manufacturing and distribution and subject to final state approval, is poised to immediately commence cultivation operations.

Hayward, California

Clawiter Road and Enterprise Avenue Buildings

The Hayward Facilities consist of two adjacent buildings with an existing Class 5 clean room as part of the 18,000 square foot building and 11,000 square feet of greenhouses for cultivation. The Hayward operation includes cultivation of high-quality greenhouse material for extraction, a flagship retail store, a delivery hub for the entire East San Francisco Bay area, CO2 extraction, formulation, isolation and contract product development. The Hayward campus totals approximately 35,000 square feet and is also planned to offer “white labeling” services to provide new or existing brands to introduce products to the California marketplace

Juva Life received approval of their CUP in October 2020. Management expects construction of the R&D lab to be completed, and the lab facilities to be licensed and operational by the end of Q1 2021. Juva further expects construction on the cultivation, retail, manufacturing area and distribution facilities at the Hayward buildings to be completed, licensed and operational by the end of Q3 2021.

Redwood City, California

Convention Way Facility, Redwood City Offices

Non-storefront retail (delivery) cannabis facility. This delivery operation services the Bay Area Peninsula from San Francisco to San Jose. Juva believes its dispatch service area encompasses approximately 1.67 million potential customers. Juva obtained approval of its local Redwood City Cannabis Business Permit and Conditional Use Permit in May, 2019, and the State license was issued in September 2019. The Corporation formally began delivery operations in January of 2020 and has seen double digit growth quarter on quarter. Additionally, Juva occupies approximately 2,000 square feet of office space used for executive offices in Redwood City, CA.

Mr. Doug Chloupek, CEO and Founder of Juva Life Inc. notes, “Coming on the heels of our recent launch onto the North American markets, we are delighted to announce our entry into the European marketplace via our Frankfurt market listing today. We welcome the interest and support of this highly engaged investment community and look forward to a mutually advantageous journey together. We are excited to continue building our consumer brand and in advancing a number of ambitious agendas including our proposed Life Sciences program to develop and fast track new and innovative formulations that we believe will positively impact a potential base of health and wellness afflicted individuals around the globe. To achieve these goals, we sincerely value our expanding relationship with an increasingly global investment community and look forward to working together as we build value for our shareholders by rapidly growing our exciting enterprise.”

In related news, the Company advises it has hired Media Relations Publishing for the fee of €350,000 for marketing and communications services.

As part of the Company’s disclosure obligations as a public issuer, ongoing financial and material filings can be found on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Commences Trading Under CSE Ticker Symbol JUVA

Juva Life Commences Trading Under CSE Ticker Symbol JUVA

Multi-Faceted California Life Sciences Cannabis Operator Launches into Public Markets

VANCOUVER, BC, — (GLOBE NEWSWIRE – November 17, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (“Juva Life,“Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and formulations, is pleased to announce the commencement of trading its common shares on the Canadian Securities Exchange (“CSE”) under the ticker symbol “JUVA.” Additional information is being updated on the Company website at www.juvalife.com.

Juva Life Inc. USA, a California corporation and wholly owned subsidiary of Juva Life Inc. (as of May 30, 2019) was originally incorporated in 2018 and represents the culmination of decades of concentrated effort in the cannabis sector. Juva Stockton Inc., a wholly owned subsidiary of Juva Life Inc., holds a Conditional Use Permit (“CUP”) from the city of Stockton, California which, subject to certain conditions, permits the Company to cultivate, manufacture, distribute and deliver cannabis for the medical and recreational markets within the State. Juva Stockton successfully launched its delivery service from this location on the 16th of October 2020. Additionally, in January 2020, after a 2.5-year process, Precision Apothecary Inc, a wholly owned subsidiary of Juva Life Inc., now holds a CUP allowing for a Microbusiness operation in the City of Hayward, California. This permit allows Juva to cultivate, manufacture, distribute and operate a retail cannabis storefront and delivery business in that municipality. Concurrently, the Company’s Redwood City delivery location has been fully operational since February 2020 and has experienced double-digit growth month over month since commencement of operations.

Under the guidance of founder & CEO Doug Chloupek, the Juva Life team brings together over 20 years of extensive leadership experience in the cannabis sector. Their knowledge and experience provide operational oversight and understanding of the California cannabis market. The Company is comprised of six divisions: cultivation, research, manufacturing, distribution, retail, and delivery. Each division services specific vertical markets within a fully integrated framework under the guiding premise of commercially engaging the many ways cannabis can fundamentally improve individual quality of life.

Mr. Doug Chloupek, CEO and Founder of Juva Life Inc. states, “Our journey has been truly extraordinary to-date. We are extremely grateful to have completed an extraordinarily successful Regulation-A+ financing along with several traditional financings. These financings have provided us the cash on hand to execute our strategy while concurrently moving ahead with today’s public listing and access to an even broader investment community. We are thrilled to start our journey as a publicly listed issuer today. We sincerely value the participation of the investment community and have made it a key pillar and measure of our success to strategically build shareholder value as we forge ahead in this exciting and evolving industry sector.”

As part of the Company’s disclosure obligations as a public issuer, ongoing financial and material filings can be found on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular entities for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

 The CSE does not accept responsibility for the adequacy or accuracy of this release.


Redwood City’s First Licensed Cannabis Delivery Company Expands

Redwood City’s First Licensed Cannabis Delivery Company Expands

Juva Delivery™ Extends Service Areas for the San Francisco Peninsula and Adds Contactless Pre-pay Option

San Jose, Calif. – July 31, 2020: Juva Delivery, a division of vertically-integrated Juva Life, Inc., is expanding its service areas this week. The company offers white-glove service across the greater parts of Santa Clara and San Mateo counties. Located at the heart of the San Francisco Peninsula, this location brings legal cannabis delivery to an underserviced area where surrounding cities have yet to adopt commercial cannabis activity.

Juva Delivery will add Brisbane, Colma, Daly City, South San Francisco, and Broadmoor to the north, and Los Altos, Cupertino, Sunnyvale, West Santa Clara, and Loyola to the south.

The company began service to San Bruno, Burlingame, San Mateo, Foster City, Hillsdale, Belmont, San Carlos, Redwood City, Atherton, Menlo Park, Palo Alto, Woodside, Portola Valley, Los Altos Hills, Millbrae, and Mountain View in late January 2020. Since opening, Juva Delivery has seen double-digit sales growth week-over-week. In addition to their Redwood City location, Juva Life has received state approval for cannabis delivery in Stockton, CA, and is locally approved for delivery and storefront retail in Hayward, CA.

A cannabis retail industry veteran, CEO Doug Chloupek stated, “Our Redwood City location has been well received on the Peninsula and continues to receive stellar customer reviews. We’ve also forged incredible relationships with specific business groups including the Redwood City Chamber of Commerce, and the San Mateo County/Silicon Valley Convention and Visitors Bureau. Our Redwood City team did an incredible job during ‘shelter-in-place’, and they are looking forward to serving more customers on the Peninsula.”

Ever mindful of customers’ health, comfort, and well-being, Juva Delivery now offers contactless pre-payment options through Paytender, a secure, fee-free online payment service.

John Hutar, President of the San Mateo County/Silicon Valley Convention and Visitors Bureau, noted, “Juva Delivery was the first cannabis company to join the Convention and Visitors Bureau. They’ve been very proactive and responsive to the needs of our other members, including co-hosting an informative webinar with us and offering discounts to hospitality industry staff furloughed during the shutdowns. We are thrilled they are continuing to grow.”

ABOUT JUVA LIFE™

Juva Life is vertically integrated and consists of six divisions: Juva Cultivation, Juva Research, Juva Manufacturing, Juva Distribution, Juva Retail, and Juva Delivery. Each division plays a crucial role in its overall goal of helping people feel better.  Founded by pioneers in the science and industry of cannabis, and guided by a team of highly-acclaimed medical professionals, Juva Life is committed to bringing a higher level of information, truth, and transparency to the marketplace. Juva Life’s core focus is improving the well-being of its customers and team members alike by providing the highest-quality cannabis products and educational resources to make positive lifestyle choices. They are proud to be a people-first organization, with deep roots in the local community. You can learn more at www.JuvaLife.com and www.ShopJuva.com. Juva Delivery (Redwood City) is a BCC-licensed delivery service: C9-0000289-LIC.

Disclaimer:
This news release is not an offer to purchase securities or offer to sell securities and should not be construed as such. It contains forward-looking statements, including statements regarding our product development, business strategy, and product offering. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and market value could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements that we may make. Except as expressly required by law, Juva Life disclaims any intent or obligation to update these forward-looking statements.

###

Contact: Heidi Minx
press@juvalife.com